Loading clinical trials...

Aortic Stenosis With COmplex PCI (ASCOP) Features Retrospective Registry on Contemporary Management and Outcomes | Clinical Trials | Clareo Health

COMPLETED

Aortic Stenosis With COmplex PCI (ASCOP) Features Retrospective Registry on Contemporary Management and Outcomes

NCT05750927•Niguarda Hospital

View on ClinicalTrials.gov

Summary

To describe the prevalence and clinical features of patients with severe aortic stenosis undergoing TAVI and concomitant clinically indicated, complex and/or high-risk PCI

Detailed Description

The aims of this study are: * to describe the prevalence and clinical features of patients with severe aortic stenosis undergoing TAVI and concomitant clinically indicated, complex and/or high-risk PCI * to depict the different possible strategies that are currently employed in this context and to retrospectively analyze outcomes * to investigate predictors of better outcomes

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Severe, symptomatic aortic stenosis with an indication to TAVI
•2. Concomitant, stable CAD with an indication to complex PCI, as anticipated by angiography, defined as follows (one or more features)
•1. Left-main (LM) CAD or proximal left anterior descending (LAD) / left circumflex (LCx) lesions requiring LM-PCI
•2. Three-vessel disease
•3. Last remaining vessel
•4. Bifurcation PCI (proximal bifurcation)
•5. Severely calcified lesions requiring calcium plaque modification (rotational/orbital atherectomy, intravascular lithotripsy, scoring or cutting balloon)
•6. Lesion length \> 30 mm
•7. Severely depressed Left ventricular function requiring mechanical circulatory support (intra-aortic balloon pump - IABP, Impella, Extracorporeal Membrane Oxygenation - ECMO

Locations (1)

ASST GOM Niguarda

Milan, Italy

Key Dates

Start Date

December 1, 2022

Primary Completion Date

October 1, 2023

Completion Date

December 31, 2023

Last Updated

March 21, 2024

Enrollment

100

ACTUAL participants

Conditions

Aortic Valve StenosisTranscatheter Aortic Valve ReplacementAngioplasty, Balloon, CoronaryCoronary Artery Disease

Interventions

Transcatheter aortic valve intervention (TAVI) and percutaneous coronary intervention (PCI)

PROCEDURE

Post-Dilatation Effect on TAVI Prostheses Expansion

NCT07477002

Aortic Valve Stenosis

View study

RECRUITINGPHASE4

ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement

NCT05672836

Aortic Valve StenosisHeart Failure

View study

RECRUITINGPHASE3

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 21, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Aortic Stenosis With COmplex PCI (ASCOP) Features Retrospective Registry on Contemporary Management and Outcomes

Inclusion Criteria

Post-Dilatation Effect on TAVI Prostheses Expansion

ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement

Short Versus Long Antiplatelet Therapy After TAVI

Effect of Fetal Aortic Valvuloplasty on Outcomes

Translational-Omics in Aortic Stenosis (TOmAS) Biobank

Structured Shared Decision Making for Patients Undergoing SAVR or TAVR